Quinazoline protein tyrosine phosphatase inhibitors
申请人:Berthel Joseph Steven
公开号:US20060211715A1
公开(公告)日:2006-09-21
The present invention comprises aminoquinazoline compounds of the general formula I:
wherein X is an unsubstituted or substituted phenyl, or is an unsubstituted or substituted 5 or 6 membered heteroaromatic ring. The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
Quinazoline Protein Tyrosine Phosphatase Inhibitors
申请人:Berthel Steven Joseph
公开号:US20090105477A1
公开(公告)日:2009-04-23
The present invention comprises aminoquinazoline compounds of the general formula I:
wherein X is an unsubstituted or substituted phenyl, or is an unsubstituted or substituted 5 or 6 membered heteroaromatic ring. The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
A general synthesis of N-substituted 1,4-benzoxazine- and 1,4-benzothiazine-2-carboxylates via copper-catalyzed intramolecular amination of arylbromides
Starting from ortho-bromosubstituted phenoxyacetates or (phenythio)acetates and primary amines, various N-substituted 4H-1,4-benzoxazine- and 4H-1,4-benzothiazine-2-carboxylates were synthesized in moderate to high yields by using a Cu(I)-catalyzed Ullmann-type cyclization as a key step. The method is simple to operate, tolerates many functional groups and does not require any additives. (C) 2011 Elsevier Ltd. All rights reserved.
[EN] The present invention is concerned with compounds of formula (1), wherein R1, R2 and X are as defined in the description and claims. The compounds of the present invention are PTP-1B inhibitors and can be used as medicaments. [FR] La présente invention concerne des composés de formule (1), dans laquelle R1, R2 et X sont tels que définis dans le descriptif et les revendications. Les composés de l'invention sont des inhibiteurs de PTP-1B et peuvent être utilisés comme médicaments.